LRRFIP1 and lung cancer: Knockdown of LRRFIP1/GCF2 reversed EMT, with the increased expression of E-cadherin, an epithelial marker, and the decreased expression of vimentin, a mesenchymal marker, and the migration and invasion capacities of pancreatic and lung cancers being significantly inhibited [73].